Zeltiq Aesthetics Inc (ZLTQ) was Reiterated by Stifel to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 52 from a previous price target of $38 . Stifel advised their investors in a research report released on Sep 21, 2016.
Many Wall Street Analysts have commented on Zeltiq Aesthetics Inc. Company shares were Reiterated by Maxim Group on Aug 9, 2016 to “Buy”, Firm has raised the Price Target to $ 48 from a previous price target of $40 .
On the company’s financial health, Zeltiq Aesthetics Inc reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 8, 2016. Analyst had a consensus of $-0.04. The company had revenue of $89.50 million for the quarter, compared to analysts expectations of $79.68 million. The company’s revenue was up 38.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
Zeltiq Aesthetics Inc closed down -0.42 points or -1.07% at $38.97 with 5,40,276 shares getting traded on Tuesday. Post opening the session at $39.58, the shares hit an intraday low of $38.82 and an intraday high of $39.9 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Sep 19, 2016, Kevin C Oboyle (director) sold 7,500 shares at $40.08 per share price. According to the SEC, on Sep 16, 2016, Carl Lamm (Vice President of Operations) sold 3,125 shares at $40.00 per share price. On Sep 14, 2016, Mark J Foley (President and CEO) sold 10,000 shares at $37.69 per share price, according to the Form-4 filing with the securities and exchange commission.
ZELTIQ Aesthetics Inc. is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product the CoolSculpting System is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers. Consumables are the CoolSculpting procedure packs that it sells which are needed to perform procedures using its CoolSculpting system. As of December 31 2014 it had an installed base of 3176 CoolSculpting systems installed across approximately 2688 practices across the world. As of December 31 2014 1.5 million CoolSculpting cycles had been shipped to its customers and distributors.